Real World Retina: Challenges in the Management of Retinal Diseases - Best of DME & DR

1.50 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Faculty Photo with retina graphic


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Activity Description

The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into treatment protocols for patients with neovascular retinal diseases has provided significant visual and anatomic improvements. However, real-world outcomes are often suboptimal compared to those seen in the pinnacle clinical studies. Some of these inconsistencies have been attributed to loss of patient adherence due to treatment burden associated with dosing schedules and undertreatment of disease with anti-VEGF therapies. Through the continued refinement of treatment protocols and dosing schedules, these discrepancies are being addressed, but other aspects of management must be taken into consideration to provide optimal care of these patients. In this activity, retina experts will provide discussion of and guidance on the management of diabetic macular edema (DME) and diabetic retinopathy (DR). This discussion will include utilization of imaging for early diagnosis and prompt treatment initiation, guidelines for disease management, identification of baseline factors that help predict anti-VEGF therapy outcomes, as well as review of real-world treatment outcomes.

Target Audience

The intended audience for this activity is retina specialists, ophthalmologists, and other health care professionals involved in the management of patients with neovascular retinal disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the evidence for anti-VEGF treatment outcomes in diabetic macular edema and diabetic retinopathy in clinical practice.
  • Identify relevant patient baseline factors for predicting anti-VEGF therapy outcomes in patients with diabetic macular edema and diabetic retinopathy.
  • Assess the applicability of recent advances in imaging to monitor treatment response in patients with diabetic macular edema and diabetic retinopathy.

Activity Chair

W. Lloyd Clark, MD
Palmetto Retina Center, LLC
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Columbia, SC


Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine 2009-2020
St. Louis, MO

Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
Milwaukee, WI

John W. Kitchens, MD
Vitreoretinal Surgeon
Retina Associates of Kentucky
Lexington, KY

Andrew A. Moshfeghi, MD, MBA
Associate Professor of Clinical Ophthalmology
Medical Director of the USC Roski Eye Institute
Director of Clinical Trials
Director of the Retina Fellowship Program
Keck Medicine of USC
Los Angeles, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, November 30, 2021, to November 29, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

W. Lloyd Clark, MD
Consulting Fee: Genentech/Roche, Regeneron
Contracted Research: Bayer, Genentech/Roche, Kodiak, Regeneron
Speakers Bureau: Genentech/Roche, Regeneron

Nancy M. Holekamp, MD
Consulting Fee: Adverum, Allergan, Apellis, Bayer, Clearside, Gemini, Genentech, Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, Regeneron
Contracted Research: Gemini, Genentech, Gyroscope, Notal Vision, Regeneron
Intellectual Property/Patent: Katalyst Surgical
Speakers Bureau: Allergan, Genentech, Novartis, Regeneron, Spark

Consulting Fee: Adverum, Alimera, Allergan, Genentech, Lineage, Notal Vision, Novartis, Regeneron

John W. Kitchens, MD
Consulting Fee: Alcon, Alimera, Allergan, Apellis, Bayer, Genentech, Optos, Regeneron, Roche, Zeiss
Speakers Bureau: Bayer, Regeneron

Andrew A. Moshfeghi, MD, MBA
Consulting Fee: Allergan, Genentech/Roche, Novartis, Ocular Therapeutix, Placid0, Pr3vent, Regeneron
Contracted Research: Genentech/Roche, Novartis, Regeneron
Ownership Interest: Ocular Therapeutix, Optistent, Placid0, Pr3vent

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at